Prostate-Specific Antigen (PSA): Test, Levels, Results, and Limitations

ARTICLE SUMMARY

Prostate-specific antigen (PSA) is a protein made mainly by the prostate. A PSA blood test measures the amount that enters the bloodstream. The test is used to help assess the risk of prostate cancer and to monitor people who have been diagnosed or treated. A raised PSA does not mean cancer is present. Age, prostate enlargement, inflammation, infection, prostate procedures, and some medicines can affect the result. PSA testing has benefits and limitations, so results are interpreted together with age, risk factors, previous PSA values, examination findings, imaging, and other tests. An abnormal result often needs confirmation before further investigation.

Cite as: Prostate-Specific Antigen (PSA): Test, Levels, Results, and Limitations. Brisbane (AU): Exon Publications; 2024 Apr 21 [updated 2026 Aug 19].

INTRODUCTION

Prostate-specific antigen, usually called PSA, is one of the most widely used blood markers in prostate health. It is not a test that can diagnose prostate cancer by itself. Instead, the PSA level helps doctors estimate whether there may be a problem in the prostate and whether further assessment is needed. PSA is also important after prostate cancer has been diagnosed because changes in the level can help monitor the disease and its response to treatment (1).

WHAT IS PROSTATE-SPECIFIC ANTIGEN?

PSA is a protein made mainly by cells in the prostate gland. The prostate is a small gland below the bladder that forms part of the male reproductive system. PSA is released into semen, where it helps make semen more fluid after ejaculation. A small amount of PSA normally passes into the bloodstream (1).

Both normal prostate cells and prostate cancer cells can produce PSA. For this reason, PSA is prostate-specific but not cancer-specific. A high blood PSA level can occur with prostate cancer, but it can also occur when no cancer is present.

The usual PSA blood test measures total PSA, which includes PSA that circulates freely in the blood and PSA attached to other proteins. Results are commonly reported as nanograms per milliliter (ng/mL) or micrograms per liter (µg/L).

WHY CAN PSA LEVELS RISE OR FALL?

PSA levels vary between people and may also change in the same person over time. Prostate cancer is one possible cause of a raised PSA, but many noncancerous factors can affect the result (2).

Age and prostate size: PSA levels tend to increase with age. One reason is that the prostate commonly becomes larger as people get older. Benign prostatic hyperplasia (BPH), which is noncancerous enlargement of the prostate, can therefore increase PSA.

Inflammation and infection: Prostatitis, which is inflammation of the prostate, and urinary tract infections can raise PSA. Acute urinary retention, where the bladder cannot empty properly, can also cause a temporary increase.

Sexual activity: Ejaculation may temporarily increase PSA in some people. This effect is usually short-lived.

Prostate procedures: A prostate biopsy and some other procedures involving the prostate or urinary tract can temporarily increase PSA.

Medicines and hormones: Medicines called 5-alpha-reductase inhibitors, including finasteride and dutasteride, can substantially lower PSA. Hormonal changes and treatments that affect testosterone can also influence the result (2).

These factors are important because a PSA result should not be interpreted without knowing the person's medical history, medicines, recent procedures, and previous PSA values.

WHAT DOES A PSA RESULT MEAN?

There is no single PSA value that can divide everyone into “cancer” and “no cancer.” The chance of prostate cancer generally increases as PSA rises, but cancer can occur at relatively low PSA levels, while some people with much higher levels do not have cancer (1, 3).

Doctors therefore consider the PSA result together with factors such as age, family history, ancestry, genetic risk, previous PSA results, prostate size, symptoms, and findings from other tests. A change over time may also provide useful information.

A PSA level above an action threshold does not mean that prostate cancer has been diagnosed. It means that the result may need to be repeated or investigated further. This distinction is important because PSA naturally varies. Current guidelines recommend confirming a newly elevated PSA before moving directly to imaging, additional biomarkers, or biopsy (2, 3).

WHO SHOULD CONSIDER PSA TESTING?

Recommendations for PSA testing differ between countries, so the decision should follow local guidance and take individual risk into account. Shared decision-making is important because testing has both potential benefits and harms (2, 3).

Australia introduced updated national guidelines in 2026. For people at usual risk who choose testing, PSA testing every two years is recommended from ages 50 to 69. People aged 45 to 49 who are not at higher risk may be offered an initial PSA test if they are interested in their prostate health, but routine testing is not recommended for this group (2).

People at higher risk may be offered testing every two years from age 45. Higher-risk groups include those with a significant family history of prostate cancer, Black people of sub-Saharan African ancestry, and people with a BRCA2 gene mutation. Certain inherited cancer syndromes can also increase prostate cancer risk (2).

For people aged 70 and older, the decision is more individualized. The Australian guideline recommends considering general health, other medical conditions, life expectancy, and personal preferences. Testing is generally not recommended when life expectancy is seven years or less (2).

These age ranges are not universal. Other national guidelines may recommend somewhat different starting ages, intervals, and stopping points.

WHAT HAPPENS IF PSA IS ELEVATED?

A newly elevated PSA usually does not lead directly to a prostate biopsy. The first step is often to repeat the blood test because PSA levels can fluctuate and may return to a lower level (2, 3).

The doctor may also look for reasons for a temporary rise, such as urinary infection, urinary retention, recent ejaculation, or a recent prostate procedure. Medicines that lower PSA should also be taken into account.

If the PSA remains elevated, the next step depends on the person's overall risk. In Australia, the 2026 guideline uses age- and risk-based PSA action levels. For people aged 50 to 69 who are not at higher risk, a PSA of 3.0 µg/L or higher should usually be repeated within one to three months. Lower action levels are used for younger people at higher risk (2).

If the elevation is confirmed, referral for further assessment may be appropriate. This may include a multiparametric magnetic resonance imaging (mpMRI) scan of the prostate. The 2026 Australian guideline recommends prostate mpMRI before biopsy in people who require specialist investigation. MRI can identify suspicious areas and help determine whether a biopsy is needed and where tissue samples should be taken (2, 4).

A biopsy is the test that allows prostate tissue to be examined for cancer. PSA alone cannot provide that diagnosis.

WHAT ARE FREE PSA, PSA DENSITY, AND PSA VELOCITY?

When a standard PSA result does not provide enough information, other ways of looking at PSA may help estimate the chance of clinically important prostate cancer (4).

Free PSA: Some PSA circulates freely in the blood, while some is attached to proteins. The percentage of PSA that is free can help with risk assessment, particularly when total PSA is moderately elevated. A lower proportion of free PSA is generally associated with a greater chance of prostate cancer, but the result is not diagnostic by itself.

PSA density: PSA density compares the PSA level with the size of the prostate. A large benign prostate can produce more PSA simply because it contains more prostate tissue. PSA density helps place the blood result in this context and is often calculated using prostate volume measured by MRI or ultrasound.

PSA velocity: PSA velocity describes how quickly PSA changes over time. A rapidly rising level may attract attention, but PSA velocity should not be used by itself to decide whether someone needs imaging or a biopsy. Age, absolute PSA level, previous results, prostate size, imaging findings, and other risk factors remain important (3, 4).

Other blood or urine tests, including the Prostate Health Index and several newer biomarker tests, may sometimes be used when their results are likely to change the decision about biopsy. Their availability varies between countries (4).

HOW IS PSA USED AFTER PROSTATE CANCER TREATMENT?

PSA has an important role after prostate cancer has been diagnosed. It can help show whether treatment has controlled the disease and whether cancer may have returned.

After radical prostatectomy, the entire prostate is removed. PSA is therefore expected to fall to an undetectable or extremely low level. A confirmed rise during follow-up may indicate that prostate cancer cells remain or have returned (5).

After radiation therapy, the prostate remains in the body, so some PSA may continue to be produced. PSA usually falls more slowly than after surgery and may take years to reach its lowest level. Doctors therefore interpret PSA differently after radiation therapy and focus on the pattern of change rather than expecting an immediately undetectable result (5).

PSA is also used during active surveillance and in people receiving treatment for advanced prostate cancer. In these settings, the PSA trend is considered together with imaging, examination findings, biopsy results, symptoms, and other clinical information. A change in PSA does not always mean that treatment must change immediately.

WHAT ARE THE BENEFITS AND LIMITATIONS OF PSA TESTING?

The main benefit of PSA testing is that it can identify a possible prostate cancer before symptoms develop. Large randomized studies have shown that organized PSA-based screening can reduce the risk of dying from prostate cancer in some groups (6). Earlier detection can also identify cancers while treatment with curative intent remains possible.

The main limitation is that PSA cannot reliably distinguish cancer from noncancerous prostate conditions. A raised result may lead to repeat blood tests, MRI, biopsy, worry, and sometimes the diagnosis of a slow-growing cancer that would never have caused illness during the person's lifetime. This is known as overdiagnosis. Overdiagnosis can lead to unnecessary treatment unless low-risk cancers are managed appropriately with approaches such as active surveillance (2-4).

PSA testing can also occasionally miss cancer because some prostate cancers produce relatively little PSA.

These limitations do not make PSA useless. They explain why PSA works best as part of a risk-based pathway rather than as a stand-alone cancer test.

CONCLUSION

PSA is a valuable marker of prostate health, but a PSA result is not a diagnosis of prostate cancer. Levels can change because of age, prostate enlargement, inflammation, infection, medical procedures, medicines, and cancer. A newly elevated result is usually confirmed before further investigation. Age, inherited risk, previous PSA levels, prostate size, MRI findings, and other clinical information help determine what should happen next. PSA also remains one of the most useful tools for monitoring prostate cancer after diagnosis and treatment. Its greatest value comes from interpreting the number in the context of the individual person.

EXPLORE OTHER ARTICLES IN THE PUBLIC EDUCATION SERIES

• Enlarged Prostate (BPH): Causes, Symptoms, and Treatment Options


• Erectile Dysfunction Causes, Symptoms, Diagnosis, and Effective Treatment Options for Men


• Male Breast Cancer: Symptoms, Diagnosis, and Treatment Options for Breast Cancer in Men


• Testicular Cancer: Types, Symptoms, Diagnosis, and Treatment

REFERENCES

1. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21(2):383-391. https://doi.org/10.1200/JCO.2003.02.083


2. Prostate Cancer Foundation of Australia. 2026 Guidelines for the Early Detection of Prostate Cancer in Australia. St Leonards (NSW): Prostate Cancer Foundation of Australia; 2026. https://www.prostate.org.au/wp-content/uploads/2026/08/2026-Guidelines-for-the-Early-Detection-of-Prostate-Cancer.pdf


3. Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023;210(1):46-53. https://doi.org/10.1097/JU.0000000000003491


4. Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol. 2023;210(1):54-63. https://doi.org/10.1097/JU.0000000000003492


5. European Association of Urology. EAU Guidelines on Prostate Cancer: Follow-up. Arnhem (NL): European Association of Urology. Accessed 2026 Aug 19. https://uroweb.org/guidelines/prostate-cancer/chapter/followup


6. Hugosson J, Roobol MJ, Månsson M, et al. A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2019;76(1):43-51. https://doi.org/10.1016/j.eururo.2019.02.009

This article is part of the 'Public Education Series' initiative by Exon Publications.

Disclaimer: This article is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional about personal health concerns.

Note on External Links: External links were checked and accessible when this article was published. Their content and availability may change over time and are outside the control of Exon Publications.